DE69517683T2 - Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe - Google Patents

Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe

Info

Publication number
DE69517683T2
DE69517683T2 DE69517683T DE69517683T DE69517683T2 DE 69517683 T2 DE69517683 T2 DE 69517683T2 DE 69517683 T DE69517683 T DE 69517683T DE 69517683 T DE69517683 T DE 69517683T DE 69517683 T2 DE69517683 T2 DE 69517683T2
Authority
DE
Germany
Prior art keywords
galactosyl
epitope
compositions containing
containing alpha
vaccine substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69517683T
Other languages
English (en)
Other versions
DE69517683D1 (de
Inventor
Uri Galili
Patricia M Repik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PENNSYLVANIA MED COLLEGE
Philadelphia Health and Education Corp
Original Assignee
PENNSYLVANIA MED COLLEGE
Philadelphia Health and Education Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PENNSYLVANIA MED COLLEGE, Philadelphia Health and Education Corp filed Critical PENNSYLVANIA MED COLLEGE
Application granted granted Critical
Publication of DE69517683D1 publication Critical patent/DE69517683D1/de
Publication of DE69517683T2 publication Critical patent/DE69517683T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds
DE69517683T 1994-03-15 1995-03-13 Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe Expired - Lifetime DE69517683T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21320094A 1994-03-15 1994-03-15
PCT/US1995/003156 WO1995024924A1 (en) 1994-03-15 1995-03-13 COMPOSITIONS AND METHODS FOR VACCINES COMPRISING α-GALACTOSYL EPITOPES

Publications (2)

Publication Number Publication Date
DE69517683D1 DE69517683D1 (de) 2000-08-03
DE69517683T2 true DE69517683T2 (de) 2001-06-07

Family

ID=22794122

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69517683T Expired - Lifetime DE69517683T2 (de) 1994-03-15 1995-03-13 Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe

Country Status (6)

Country Link
US (2) US5879675A (de)
EP (1) EP0754057B1 (de)
AU (1) AU2158995A (de)
CA (1) CA2185470C (de)
DE (1) DE69517683T2 (de)
WO (1) WO1995024924A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024924A1 (en) * 1994-03-15 1995-09-21 Medical College Of Pennsylvania And Hahnemann University COMPOSITIONS AND METHODS FOR VACCINES COMPRISING α-GALACTOSYL EPITOPES
EP0799422A1 (de) * 1995-10-24 1997-10-08 Sangstat Medical Corporation Anti alpha-galactosyl nachweisverfahren
DE19626614A1 (de) * 1996-07-02 1998-01-08 Immuno Ag Komplex aus Antigen und Zellbestandteil, Impfstoffzusammensetzung, welche den Komplex enthält, pharmazeutische Präparation sowie Verfahren zur Herstellung des Komplexes
US5869035A (en) * 1996-11-13 1999-02-09 Human Gene Therapy Research Institute Methods and compositions for inducing complement destruction of tissue
EP1007569B1 (de) 1997-02-11 2009-04-08 Immunomedics, Inc. Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
JP2002511431A (ja) * 1998-04-15 2002-04-16 バクスター インターナショナル インコーポレイテッド 異種反応性抗体の阻害
AU5132499A (en) 1998-08-11 2000-03-06 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for preventing anti-gal production in xenograft recipients
US7005126B1 (en) * 1999-06-08 2006-02-28 Human Gene Therapy Research Institute Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
US6818395B1 (en) * 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2003020039A1 (en) * 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
CA2483473A1 (en) * 2002-04-22 2003-10-30 Absorber, Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
MXPA05003705A (es) * 2002-10-09 2005-08-16 Central Iowa Health System Vacunacion antitumoral usando celulas de tumor alogeneico que expresan alfa (1,3)-galactosil transferasa.
US20050201993A1 (en) 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
CN1747970A (zh) 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
US7820628B2 (en) * 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US7998486B2 (en) * 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
WO2008118487A2 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
US8084057B2 (en) * 2007-07-17 2011-12-27 University Of Massachusetts Compositions and methods for wound healing
US8865178B2 (en) 2007-07-17 2014-10-21 University Of Massachusetts Compositions and methods for wound healing
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
EP2285404B1 (de) * 2008-05-30 2016-12-21 GlycoFi, Inc. Hefestamm zur herstellung von proteinen mit terminaler alpha-1,3-verbundener galactose
AU2010319615B2 (en) * 2009-11-11 2014-07-31 Momenta Pharmaceuticals, Inc. Glycosyl transferase from Chinese hamster and related methods
WO2012135313A1 (en) * 2011-03-28 2012-10-04 University Of Massachusetts Compositions and methods for detecting allergy to a-gal epitopes
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
ES2696373T3 (es) * 2014-05-09 2019-01-15 Agalimmune Ltd Composiciones que contienen glucolípidos para ser usadas en el tratamiento de tumores
US11471420B2 (en) * 2017-04-21 2022-10-18 Coastar Therapeutics Inc. Membrane lipid coated nanoparticles and method of use
US11413252B2 (en) * 2017-04-21 2022-08-16 Coastar Therapeutics Inc. Membrane lipid coated viral nanoparticles and method of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008317A (en) * 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
WO1995024924A1 (en) * 1994-03-15 1995-09-21 Medical College Of Pennsylvania And Hahnemann University COMPOSITIONS AND METHODS FOR VACCINES COMPRISING α-GALACTOSYL EPITOPES
US5871997A (en) * 1994-07-21 1999-02-16 Alexion Pharmaceuticals, Inc. Methods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha (1,3) galactosyl epitopes

Also Published As

Publication number Publication date
WO1995024924A1 (en) 1995-09-21
EP0754057A4 (de) 1997-06-18
AU2158995A (en) 1995-10-03
CA2185470C (en) 2005-10-25
EP0754057B1 (de) 2000-06-28
EP0754057A1 (de) 1997-01-22
US5879675A (en) 1999-03-09
US6361775B1 (en) 2002-03-26
CA2185470A1 (en) 1995-09-21
DE69517683D1 (de) 2000-08-03

Similar Documents

Publication Publication Date Title
DE69517683D1 (de) Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
ATE351910T1 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
DE69609175D1 (de) Endodontisches instrument und verfahren
DE69534416D1 (de) Verfahren und formulierungen zur bekämpfung von schadinsekten
DE69723439D1 (de) Display und verfahren für digitaloszilloskop
DE69331176T2 (de) Knochenzement und Verfahren zu seiner Herstellung
DE69734658D1 (de) Verfahren und system für virtuelle kinematographie
DE19781608T1 (de) Verfahren und Vorrichtungen zum Ausgeben von Zusammensetzungsmassen
DE69511080D1 (de) Schnittstellenanordnung und verfahren
DE69520425T2 (de) Verfahren zur isotopenzusammensetzungsanalyse und isotopenzusammensetzungsanalysator
DE69428532T2 (de) Intumeszierende zusammensetzung und verfahren zum gebrauch
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
DE69602847D1 (de) Tuberkilizide synergistische desinfizierende zusammensetzung und verfahren zur desinfektion
DE69318568T2 (de) Zusammensetzungen zur entfernung von aldehyden und verfahren
DE69306678T2 (de) Dichtungsvorrichtung und Verfahren zu ihrer Herstellung
DE69735709D1 (de) Zusammensetzung und verfahren zur sanierung von zemenhaltigen materialien
DE69301771D1 (de) T-Butyl-R-(-)-4-cyano-3-hydroxybutyrat und Verfahren zu seiner Herstellung
DE69510774D1 (de) Katschukzusammensetzung und verfahren zu ihrer herstellung
DE19581575T1 (de) Verfahren und Zusammensetzung zur Bekämpfung der Umweltverschmutzung
DE69602355D1 (de) Verfahren und zusammensetzung zur reinigung von oberflächen
DE69718502D1 (de) Zahnärztliche zusammensetzung, system und verfahren
DE69526946D1 (de) Aktivierte tonzusammensetzung und verfahren
DE69732460D1 (de) Thermokopf und verfahren zu seiner herstellung
DE69523655T2 (de) Beschleunigungsmessaufnehmer und Verfahren zu seiner Herstellung

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition